This is the mp3 version. From episode 30 onward this is the same as the AAC version. Prior to that, the AAC version had chapter markings.
LAROCHE Daniel Cost effective suprachoroidal shunt (mp3)
In this episode, I talk with Daniel Laroche. We have crossed paths for many years at conferences having both started our practices at the same time, but this was the first time we sat down to record our conversation. Daniel Laroche is Director of Glaucoma Services and President of Advanced Eyecare of New York. He is affiliated with the New York Eye and Ear Infirmary, and Assistant Professor of Ophthalmology at the Mount Sinai School of Medicine, New York.
DeMORAES Gus 24--2C the origin story
In this episode, I talk with Gus DeMoraes, a frequent guest of the pod. Gus is Associate Professor of Ophthalmology at Columbia University where he serves as Medical Director of Clinical Trials. When we originally sat down to record this way back in March 2019, he had just presented some of the work he had done in collaboration with Don Hood. This has now appeared on Humphrey perimeters as the 24-2C testing strategy and is becoming a new the standard of care. It is based on reports in recent years that glaucoma damage often occurs in the macular area but missed because the standard 24-2 testing strategy only tests in 6 degree increments. These early central glaucomatous defects are often hidden between the test points.
KIM Won Combined MIGS procedures
In this episode, I talk with Won Kim, a glaucoma colleague based on Walter Reed in Bethesda, Maryland, about how he has been combining multiple minimally invasive glaucoma procedures in patients who have failed traditional glaucoma surgery. I'm Rob Schertzer, a Vancouver, Canada based glaucoma specialist, podcaster and HealthIT expert, and we're...talking about glaucoma.
LEWIS Rick Rho Kinase Inhibitors: a new class of drugs (mp3)
The goal of the late Dave Epstein was to find a drug that treats the cause of glaucoma by improving trabecular meshwork outflow. After many years of trying, Aerie Pharmaceuticals was formed and refined a Rho Kinase inhibitor called Netarsudil. In April 2018 this came to market as Rhopressa and March 2019, combined with latanoprost, as Roclatan. Today I’m talking with Rick Lewis, a glaucoma colleague based in Sacramento and Chief Medical Officer for Aerie Pharmaceuticals.
Talking About Glaucoma #30 - 5Nov2018 JOHNSTONE Murray Pulsatile Flow (mp3)
In this episode, I talk with Murray Johnstone from Seattle about pulsatile flow through the Trabecular Meshwork and collector channels. We discuss the imaging improvements over the years that have made this possible including the latest phase-based OCT scans that result in nanometre resolution instead of the micrometre resolution of spectral domain scans that most of us are using in clinical practice.
Talking About Glaucoma #29 - 29Jan2018 FELLMAN Fluid Wave (mp3)
I sat down with Ron Fellman at a recent American Glaucoma Society meeting to discuss the use of the fluid wave in assessing the aqueous humour outflow pathway and its clinical application.